Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector




















Sort by: Date|Relevance

The company revolutionizing access to care and natural remedies

The Market Online recently spoke with Liz Viccars, CEO of AJA Health and Wellness Inc. (TSXV:AJA) a company transforming healthcare with its total health access service offering telemedicine, diagnostics and specialized care via proprietary tech. Additionally, AJA Heal...

How BioVaxys' DPX platform creates anti-cancer immune response

Discover BioVaxys’ innovative DPX™ platform, a cutting-edge lipid-based delivery system transforming immunotherapy. This video explores how the company’s proprietary technology encapsulates diverse bioactive molecules, enhancing and sustai...

Buzz on the Bullboards: TSX stocks making headlines this week

The TSX experienced a dynamic week. It opened flat on Monday, but saw a significant jump on Tuesday, driven by a global increase in commodity prices following new monetary stimulus measures in China. However, the energy sector’s decline led to a breather...

Revolutionizing immunotherapies with groundbreaking DPX platform

The following is a transcription of the above video, and The Market Online has edited it for clarity . BioVaxys Technology Corp (CSE:BIOV) is a Canadian-based clinical stage biopharmaceutical company focused on improving patient lives with novel immunotherapies. CE...

Buzz on the Bullboards: Whose stocks sizzle during summer holidays?

As we get through the summer holiday season, the typically calmer market environment presents a prime opportunity for investors to evaluate their portfolios and consider new investments. The TSX continues to offer a variety of promising stocks, particularly in energ...

Buzz on the Bullboards: From innovating traffic enforcement to cancer breakthroughs

The past week on the TSX has been one for the books, with significant gains driven largely by advancements in the technology sector. The S&P 500 and NASDAQ have hit fresh highs, a clear sign of a hungry market bolstered by technology stocks. This momentum has put a spot...

BioNTech & Cardiol Therapeutics – on the verge of a breakout

Compared with the broader indices, DAX and Dow Jones, which have already reached new all-time highs, the Nasdaq Biotech Index is currently lagging. The sector index is still around 23% below its peak from August 2021. Nevertheless, the sector is on the move. In addition t...

Buzz on the Bullboards: Major developments amidst market dynamics

This week, the North American stock markets managed to showcase some contrasted performances. While the NASDAQ and S&P 500 reached record highs, driven by optimism around potential Federal Reserve rate cuts, the Dow Jones also enjoyed a solid rally. Meanwhile, the TS...

Buzz on the Bullboards: Who benefits from the latest stock market rally?

It was a more nuanced performance for stock markets in Toronto and New York this week with notable gains and splits between indices capturing investor attention. The TSX surged to highs not seen in a month, buoyed by optimism, while in the United States, some stocks ...

Takeover rumours: BioNTech, Cardiol Therapeutics and Novo Nordisk in focus

The biotech sector has significantly lagged behind the performance of artificial intelligence and high-tech this year. This is because of high inflation, which in turn has made an imminent interest rate cut unlikely. Nevertheless, Germany’s economic condit...
1 2 3 4 5 6 7 8 9 10 ...